β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer

Table 1 β1-integrin inhibitors currently in preclinical or clinical development for cancer therapy

Drug or treatment	Type of therapeutic agent	Stage	Target	Tumor model	Reference
Clone AIIB2	Rat IgG₁ mAb	Preclinical	β1-subunit	MCF-7 human breast cancer xenograft	[64]
Clone AIIB2 + ionizing radiation	Rat IgG₁ mAb + radiotherapy	Preclinical	β1-subunit	MCF-7 human breast cancer xenograft	[102]
Clone 339.1	Rat IgG₁ mAb	Preclinical	α5β1	SVR murine angiosarcoma and A673 human rhabdomyosarcoma xenografts	[95]
Volociximab	Chimeric (82% human/18% murine) IgG₄ mAb	Preclinical	α5β1	Rabbit VX2 carcinoma model	[97]
		Phase I	α5β1	Patients with advanced solid malignancies	[105]
		Phase II	α5β1	Patients with platinum-resistant advanced epithelial ovarian cancer or primary peritoneal cancer	[96]
ATN-161	Small peptide antagonist	Preclinical	α5β1	MDA-MB-231 human breast xenograft and skeletal metastasis	[99]
		Preclinical	α5β1	Lewis lung adenocarcinoma model	[98]
		Phase I	α5β1	Patients with advanced solid malignancies	[106]
ATN-161 + 5-fl uorouracil	Small peptide antagonist + chemotherapy	Preclinical	α5β1	CT26 murine colorectal liver metastasis	[100]

ISSN: 1465-542X